Book contents
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part I Clinical syndromes: general
- Part II Clinical syndromes: head and neck
- Part III Clinical syndromes: eye
- Part IV Clinical syndromes: skin and lymph nodes
- Part V Clinical syndromes: respiratory tract
- Part VI Clinical syndromes: heart and blood vessels
- Part VII Clinical syndromes: gastrointestinal tract, liver, and abdomen
- Part VIII Clinical syndromes: genitourinary tract
- Part IX Clinical syndromes: musculoskeletal system
- Part X Clinical syndromes: neurologic system
- Part XI The susceptible host
- Part XII HIV
- Part XIII Nosocomial infection
- Part XIV Infections related to surgery and trauma
- Part XV Prevention of infection
- Part XVI Travel and recreation
- Part XVII Bioterrorism
- Part XVIII Specific organisms: bacteria
- 123 Actinomycosis
- 124 Anaerobic infections
- 125 Anthrax and other Bacillus species
- 126 Bartonella bacilliformis
- 127 Cat scratch disease and other Bartonella infections
- 128 Bordetella
- 129 Branhamella–Moraxella
- 130 Brucellosis
- 131 Campylobacter
- 132 Clostridium
- 133 Corynebacteria
- 134 Enterobacteriaceae
- 135 Enterococcus
- 136 Erysipelothrix
- 137 HACEK
- 138 Helicobacter pylori
- 139 Gonococcus: Neisseria gonorrhoeae
- 140 Haemophilus
- 141 Legionellosis
- 142 Leprosy
- 143 Meningococcus and miscellaneous neisseriae
- 144 Listeria
- 145 Nocardia
- 146 Pasteurella multocida
- 147 Pneumococcus
- 148 Pseudomonas, Stenotrophomonas, and Burkholderia
- 149 Rat-bite fevers
- 150 Salmonella
- 151 Staphylococcus
- 152 Streptococcus groups A, B, C, D, and G
- 153 Viridans streptococci
- 154 Poststreptococcal immunologic complications
- 155 Shigella
- 156 Tularemia
- 157 Tuberculosis
- 158 Nontuberculous mycobacteria
- 159 Vibrios
- 160 Yersinia
- 161 Miscellaneous gram-positive organisms
- 162 Miscellaneous gram-negative organisms
- Part XIX Specific organisms: spirochetes
- Part XX Specific organisms: Mycoplasma and Chlamydia
- Part XXI Specific organisms: Rickettsia, Ehrlichia, and Anaplasma
- Part XXII Specific organisms: fungi
- Part XXIII Specific organisms: viruses
- Part XXIV Specific organisms: parasites
- Part XXV Antimicrobial therapy: general considerations
- Index
- References
151 - Staphylococcus
from Part XVIII - Specific organisms: bacteria
Published online by Cambridge University Press: 05 April 2015
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part I Clinical syndromes: general
- Part II Clinical syndromes: head and neck
- Part III Clinical syndromes: eye
- Part IV Clinical syndromes: skin and lymph nodes
- Part V Clinical syndromes: respiratory tract
- Part VI Clinical syndromes: heart and blood vessels
- Part VII Clinical syndromes: gastrointestinal tract, liver, and abdomen
- Part VIII Clinical syndromes: genitourinary tract
- Part IX Clinical syndromes: musculoskeletal system
- Part X Clinical syndromes: neurologic system
- Part XI The susceptible host
- Part XII HIV
- Part XIII Nosocomial infection
- Part XIV Infections related to surgery and trauma
- Part XV Prevention of infection
- Part XVI Travel and recreation
- Part XVII Bioterrorism
- Part XVIII Specific organisms: bacteria
- 123 Actinomycosis
- 124 Anaerobic infections
- 125 Anthrax and other Bacillus species
- 126 Bartonella bacilliformis
- 127 Cat scratch disease and other Bartonella infections
- 128 Bordetella
- 129 Branhamella–Moraxella
- 130 Brucellosis
- 131 Campylobacter
- 132 Clostridium
- 133 Corynebacteria
- 134 Enterobacteriaceae
- 135 Enterococcus
- 136 Erysipelothrix
- 137 HACEK
- 138 Helicobacter pylori
- 139 Gonococcus: Neisseria gonorrhoeae
- 140 Haemophilus
- 141 Legionellosis
- 142 Leprosy
- 143 Meningococcus and miscellaneous neisseriae
- 144 Listeria
- 145 Nocardia
- 146 Pasteurella multocida
- 147 Pneumococcus
- 148 Pseudomonas, Stenotrophomonas, and Burkholderia
- 149 Rat-bite fevers
- 150 Salmonella
- 151 Staphylococcus
- 152 Streptococcus groups A, B, C, D, and G
- 153 Viridans streptococci
- 154 Poststreptococcal immunologic complications
- 155 Shigella
- 156 Tularemia
- 157 Tuberculosis
- 158 Nontuberculous mycobacteria
- 159 Vibrios
- 160 Yersinia
- 161 Miscellaneous gram-positive organisms
- 162 Miscellaneous gram-negative organisms
- Part XIX Specific organisms: spirochetes
- Part XX Specific organisms: Mycoplasma and Chlamydia
- Part XXI Specific organisms: Rickettsia, Ehrlichia, and Anaplasma
- Part XXII Specific organisms: fungi
- Part XXIII Specific organisms: viruses
- Part XXIV Specific organisms: parasites
- Part XXV Antimicrobial therapy: general considerations
- Index
- References
Summary
Treatment of staphylococcal infection is dependent on the site involved, the severity of infection, and the antibiotic susceptibility pattern of the organism causing the infection. Although most serious staphylococcal infections are due to coagulase-positive staphylococci (Staphylococcus aureus), infections due to coagulase-negative staphylococci (e.g., Staphylococcus epidermidis) are increasing and may also be life threatening. S. aureus is a highly invasive pathogen, able to spread hematogenously to many organs, leading to metastatic foci of infection. Coagulase-negative staphylococci are generally healthcare-associated infections that require the presence of prosthetic material to gain a foothold and cause infection.
Susceptibility to antibiotics
Staphylococci have a propensity to develop resistance to antibiotics relatively quickly. Most staphylococci are no longer susceptible to the effects of penicillins alone because the bacteria produce enzymes or penicillinases that inactivate many of those drugs. One approach to the problem of antibiotic resistance in staphylococci has been the use of penicillinase-resistant penicillins, e.g., nafcillin, oxacillin, and methicillin. Alternatively, penicillins have been combined with inhibitors of penicillinase. Examples of penicillin–penicillinase-inhibitor combinations include: amoxicillin-clavulanate (Augmentin), ampicillin–sulbactam (Unasyn), piperacillin–tazobactam (Zosyn), and ticarcillin–clavulanate (Timentin). The penicillinase-resistant penicillins and penicillin–penicillinase-inhibitor combinations are effective for the treatment of penicillin-resistant, but methicillin-susceptible, staphylococci.
Other β-lactam antibiotics are also useful for the treatment of methicillin-susceptible staphylococci. First-generation cephalosporins (cefazolin, cephalexin) are the most active, followed by secondgeneration agents (cefuroxime, cefotetan, cefoxitin).
- Type
- Chapter
- Information
- Clinical Infectious Disease , pp. 985 - 990Publisher: Cambridge University PressPrint publication year: 2015